Tag: R&D

Research and development (R&D or R+D), also known in Europe as research and technical (or technological) development (RTD), is a general term for activities in connection with corporate or governmental innovation. Research and development is situated at the front end of the innovation life cycle, which may end with commercialization.

Shake-up in AstraZeneca

British pharma giant has aligned therapy R&D units to new commercial strategy and hired oncology expert Jose Baselga to lead new phase in development. AstraZeneca has announced a major shake-up...

Lupin Plans to Develop First-to-Market Products

Drug maker Lupin is in the process of developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders, a top company official sai...

Graphene Can Detect Neurodegenerative Diseases

Researchers have discovered that the sensitive nature of graphene—one of the world’s strongest materials—makes it a good candidate to detect and diagnose diseases. A team of researchers from the Un...

Collaboration of Japanese Companies in AI Drug R&D

Artificial intelligence and machine learning company InveniAI has joined with Kyowa Hakko Kirin to harness the power of technology for drug discovery. The companies are the latest to use AI and mac...

Allergan to Establish R&D presence in US

allergan
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area. Allergan will establish an R&D presence in the Kendall Square...

NeuroBo to Initiate Phase III Trial for its Lead Drug

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases announced its plans to initiate a Phase III trial to ...

GiroNex Created Novel Precision Powder Dispensing Technology

A Cambridgeshire-based technology spin-out has developed precision powder dispensing technology that could better make available patient-specific dosing for more effective treatments. GiroNex has d...

Pfizer will Use CytoReason’s Machine Learning Models for Drug Discovery

pfizer
CytoReason, a leader in machine learning for drug discovery and development, announced that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason’s cell-centered...

2018 is Record Breaker for FDA Approvals

As 2019 gets under way, the pharma industry and the US FDA can look back at a truly record-breaking 2018 for new drug approvals. The final tally for novel drug approved at the US regulator last yea...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

Amino Invests in a New R&D Center

With the construction of a new innovation center AMINO sets the foundation for the next generation of products and services. In parallel to our existing business, i.e. the production of pharmaceutica...

US Cell Therapies Company Keeps ITOCHU’s Investments

Promethera Biosciences, a US-based cell therapies company, has secured an investment of €10m from Japanese conglomerate ITOCHU as part of the company’s Series D round. ITOCHU is the first lead inve...

Chinese Pharma Collaboraton for Cancer Drug Development

InventisBio announced that it has signed a "Collaboration Agreement" with Betta Pharma. Under this agreement, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong ...

Chinese Pharma Announces Innovative Drug

Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that it has entered the final stage of New Drug A...

HJB and MabSpace Biosciences Merge to Transcenta Holding Ltd

HJB and MabSpace Biosciences (MabSpace) announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics c...

Antengene Raised $120m to Develop Inhibitors

Clinical-stage therapeutics company Antengene has raised $120m funding, which will be used to continue the development of its ATG-008 and ATG-010 (selinexor) and other clinical-stage assets. Anteng...